Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity

Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity

Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target therapy can be effective. The use of bacterial tox...

Full description

Bibliographic Details
Main Authors: Mohammad Hossein Ataee, Seyed Ali Mirhosseini, Reza Mirnejad, Ehsan Rezaie, Hamideh Mahmoodzadeh Hosseini, Jafar Amani
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Research in Pharmaceutical Sciences
Subjects:
dll3; in silico design; rovalpituzumab; sclc.
Online Access:http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2022;volume=17;issue=4;spage=428;epage=444;aulast=Ataee

Internet

http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2022;volume=17;issue=4;spage=428;epage=444;aulast=Ataee

Similar Items